Title: Liquid Plasma vs Thawed Plasma: Tracking Coagulation Factor Activity Changes During Storage

Short Running Headline: Liquid Plasma vs Thawed plasma

Authors: Nalan Yurtsever[1], Catherine Gereg[1], Nichelle Perera[1], Parveen Bahel[2], Henry M. Rinder[1], Edward L. Snyder[1], Christopher A. Tormey[1], Edward S. Lee[1]

Institutions:

1. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
2. Department of Laboratory Medicine, Yale New Haven Hospital, New Haven, CT, USA

Corresponding author: Nalan Yurtsever, MD

Contact info: nalan.yurtsever@yale.edu

Conflict of interest statement: Authors declare no conflict of interest.

Data availability statement: The data supporting the findings of this study are publicly available and can be downloaded from github.com/edwardslee/liquidplasma

Funding: Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T32HL007974-23. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Number of words: 4483/5000

Abstract

Background and Objectives

Liquid plasma (LQP) stands out as an alternative to thawed plasma (TP) for emergent transfusions due to longer shelf life. We aim to measure fibrinogen, Protein C, Protein S, FV, FVII, and FVIII activity in LQP, quantify how these factors levels change in LQP during storage, and characterize how they compare in LQP to TP.

Materials and Methods

Coagulation factor activities were measured on Days 15, 26, and 27 for LQP (n=26) and Day 5 for TP (n=24). Bayesian statistical modeling was used to compare coagulation factor activity and quantify changes in activity during storage.

Results

Fibrinogen and Protein C activity in Day 26 LQP (LQP26) was comparable to Day 5 TP (TP5) with posterior mean activity of 252 mg/dL vs 247 mg/dL and 100.4% vs 111.3%, respectively. FV, FVII, and FVIII had slightly lower activity in LQP26 vs TP5 with posterior mean activities of 42.6% vs 58.4%, 55.0% vs 62.2%, and 48.8% vs 55.0%, respectively. Protein S in LQP26 was low with posterior mean activity of 28.0%, which was slightly less than half that of TP5 at 64.9%. From Day 15 to Day 26, FVII in LQP decreased at a rate of -3.49% per day whereas fibrinogen, Protein C, Protein S, FV, and FVIII activity in LQP remained relatively stable.

Conclusion

Compared to TP5, LQP26 has comparable activities of fibrinogen, Protein C, FV, FVII, and FVII but lower activity of Protein S. LQP is a viable alternative for use in emergency transfusions and massive transfusion protocols.

Key words: liquid plasma, thawed plasma, factor activity, coagulation, massive transfusion protocol

Highlights:

- Liquid plasma factor activities, with the exception of protein S, are comparable to thawed plasma in terms of emergency use with the advantage of extended shelf life.
- Liquid plasma has adequate fibrinogen and Protein C levels on the last day of expiration.
- Liquid plasma has ~50% FV, FVII and FVIII levels on the last day of expiration, making it a sufficient replacement option to TP for active bleeding.

Introduction

Administration of plasma has an important role in acute trauma care as early transfusion of red blood cells, plasma, and platelets in a 1:1:1 ratio is recommended during resuscitation [1]. In the United States, plasma components can be stored frozen for long periods of time (e.g., 1 year at -18 °C or colder) but require thawing before use. Once thawed, plasma has a shelf life of 24 hours stored at 1–6 °C, and after this initial 24-hour postthaw period, plasma can be stored up to four more days as "thawed plasma" (TP). These storage requirements cause blood banks to face challenges in maintaining an active plasma inventory for rapid release. Consequently, thawed plasma units are routinely wasted to keep an inventory of plasma products immediately available for emergent indications. However, this approach can still cause delays in issuing plasma if all thawed plasma units are employed and frozen plasma components need to be thawed.

Liquid plasma (LQP) is an alternative to TP and frozen plasma products for rapid availability of plasma for resuscitation. This never-frozen product is stored at 2–6 °C and has a shelf life of 26 days, allowing for increased flexibility in inventory management and fast utilization in massive transfusion protocols [2, 3]. As such, one study investigating wastage after switching from a TP-only inventory to a mixed TP and LQP inventory observed a drop in yearly wastage rates from 13.5% to 10.3%. Another study showed that implementation of LQP resulted in a significant improvement in 24-hour plasma:RBC transfusion ratios from 1:1.72 to 1:1.23 and observed reductions in hospital length of study, 24-hour mortality, and acute kidney injury [4]. Multiple other retrospective studies showed no difference between TP and LQP for length of stay and survival [5-8].

Yet, there has been limited evaluation of the hemostatic profile of LQP. One study performed thromboelastogram measurements of TP and LQP and found significantly higher maximum amplitude, shear elastic modulus strength, and total thrombus generated in LQP, which was partly attributed to increased residual platelets in LQP [9]. In addition, during storage, LQP had significant loss of labile coagulation factors such as factor V, factor VIII, and protein S, but other factors

maintained stable levels. LQP is also shown to be as effective as TP in blocking endothelial permeability [10].

In this study, we aim to characterize how select coagulation factor levels change in liquid plasma units during storage. We performed serial measurements in LQP units at mid-expiration (Day 15), on the day of expiration (Day 26), and the day after expiration (Day 27). Day 27 measurements were included to see if any changes in coagulation factor activity occur after expiration. Additionally, we compare coagulation factor levels in LQP to TP on the final day of storage (Day 5) to compare the hemostatic profile of these plasma products.

Materials and Methods

Measurement of coagulation factors in liquid plasma and thawed plasma

We obtained 26 units of liquid plasma and 24 units of fresh frozen plasma (FFP) from the American Red Cross (Farmington, CT). Liquid plasma units were all blood group A, and thawed plasma units were A, O, or AB. All plasma units were derived from blood collected in citrate-phosphate-dextrose. All LQP units were irradiated upon arrival at our blood bank. To obtain units of thawed plasma at Day 5 (TP5), FFP was thawed in a water bath at 37°C according to standard AABB operating procedures and stored at 1–6°C for 5 days. Aliquots of LQP were obtained from the same units on Day 15, Day 26 (day of expiration), and Day 27 (1 day after expiration) by either using segments included with the unit or using sterile connections (Terumo TSCD-11 Sterile Tubing Welder, Terumo BCT, Highlands Rach, Colorado, U.S.) and then were frozen and stored at −70°C until time of testing of coagulation factors. Aliquots of TP5 were similarly obtained at Day 5 of storage and were frozen and stored at −70°C until time of testing. On the day of testing, aliquots were thawed at 37°C in a water bath. Samples that looked unclear or turbid were centrifuged (10,000 rpm × 10 minutes) to remove any debris.

We measured the activity level of Factor V (FV), Factor VII (FVII), and Factor VIII (FVIII) to account for common, extrinsic, and intrinsic pathways along with fibrinogen to account for the final step of plasma hemostasis. We also measured Protein C (PC) and Protein S (PS) activities since previous studies found LQP to be

lower in PS than FFP. FV, FVII, FVIII, PC, and PS activities were tested using a clinical-grade assay (ACL TOP 750, Bedford, MA) based on prothrombin time correction of factor deficient plasma and expressed as percent activity. Fibrinogen was tested using a quantitative clot-based assay (Siemens CS-5100, Malvern, PA). The normal range for human plasma factor levels at our facility is established by reference range studies of normal individuals. This study was reviewed by the Institutional Review Board of Yale University and was determined to not constitute human subjects research.

Statistical Analysis

We employed Bayesian statistical models for estimating the average coagulation factor activities in LQP at Day 15 (LQP15), LQP at Day 26 (LQP26), LQP on Day 27 (LQP27), and TP5, the difference in factor activities between LQP26 and TP5, and the rate of change of coagulation factor activity in LQP during storage.

We used a Student-t distribution model to estimate the average coagulation factor activities in LPQ and TP5. For each coagulation factor and each time point, the data are the measured factor activity f_i for unit i, and the factor activity levels have a Student-t distribution with mean μ and standard deviation σ

$$f_i \sim \text{Student}(2,\ \mu,\ \sigma)$$

where the shape parameter ν is fixed to be 2 (see Supplementary Information (SI), Section S5). Full details are described in SI, Section S2.

To compare the coagulation factor levels in LQP27 and TP5, we adapted a Bayesian version of the two-sample t-test [11]. The factor activity data f_i for LQP and TP5 have a Student-t distribution and are modeled as

$$f_i \sim \text{Student}\left(2, \mu_{\text{Product}_i}, \sigma_{\text{Product}_i}\right)$$

where $\text{Product}_i \in \{\text{LQP26}, \text{TP5}\}$. The posterior difference between the means of the two plasma products is calculated as $\mu_{\text{LQP26}} - \mu_{\text{TP5}}$. Full statistical details are described in SI, Section S3.

To characterize the change in coagulation factor activity over storage time, we developed multilevel piecewise linear regression models adapted from a previously described approach to model how factor activity levels change with storage time [12]. These models estimate the change per storage day from day 15 to day 25 and

the change per day from Day 26 to Day 27, allowing for inferences on the magnitude and timing of changes in coagulation factor levels during storage. In addition, since we repeated measurements at different timepoints from each individual unit, we utilized a Bayesian multilevel structure to estimate individual per-unit random effects and then used partial pooling to estimate population level effect sizes. For a given coagulation factor, the measured factor activity f_i at storage time t_i were modeled as

$$f_i \sim \text{Student}(2, \mu_i, \sigma)$$

$$\mu_i = \alpha + \beta_{\text{Unit}[i]}(t_i - 26)I\big(26 - t_j\big) + \gamma_{\text{Unit}[i]}(t_i - 26)I(t_i - 26)$$

where $I(.)$ is the indicator function. Here, $\beta_{\text{Unit}[i]}$ is the individual rate of change in factor activity per day from Day 15 to Day 26 of storage for plasma unit i, and $\gamma_{\text{Unit}[i]}$ is the individual rate of change per day in factor activity from day 26 to day 27 of storage for plasma unit i. The parameters $\bar{\beta}$ and $\bar{\gamma}$ are population rate of change from Day 15 to Day 26 and from Day 26 to Day 27 respectively (see SI, Section S4).

We use weakly informative or informative priors for all parameters, which that were motivated by previously described factor levels in other plasma products [13]. Full details of all statistical models, including priors and model specifications, are in SI, Sections S2–S4.

We used the Hamiltonian Monte Carlo engine Stan (v2.36) to estimate posterior distributions of each model with R (v4.4.3) using CmdStanR and rethinking packages [14-16]. Statistical models were either coded directly in the Stan language or with the rethinking package using the ulam function. Each model was run with 4 HMC chains of 10,000 samples per chain in parallel with half as warmup until convergence achieved as suggested by high effective sample sizes, R-hat estimates of 1.00, and visual inspections of traceplots. Bayesian statistical inference does not return point estimates for parameters but instead provides a posterior distribution for possible parameter values, and posteriors are summarized with the posterior mean values and 95% credible intervals. Data and code implementing the models are available on github.com/edwardslee/liquidplasma.

Results

We analyzed the activities of fibrinogen, PC, PS, FV, FVII, and FVIII in 26 LQP units on Days 15, 26, and 27 of storage and in 24 TP5 units (Figure 1A). The posterior mean estimates for the average coagulation activity with 95% credible intervals are shown in Table 1, and observed descriptive statistics are shown in Tables S1–S2. The posterior mean factor activity in LQP15 for fibrinogen was 241 mg/dL (95% CI: 228, 254 mg/dL) and PC was 110.6% (95% CI: 102.8%, 118.7%), which are within 1 standard deviation of previously reported average activity levels in FFP and PF24 at time of thaw [13, 17]. In contrast, the posterior mean factor activity in LQP15 for protein S was 35.3% (95% CI: 27.1%, 43.6%), for FV was 37.0% (95% CI: 33.9%, 40.8%), for FVII was 66.1% (95% CI: 55.0%, 80.0%), and for FVIII was 56.0% (95% CI: 51.8%, 60.2%), which are lower than previously reported averages in FFP and PF24. [13, 17] The estimated mean activity levels in all coagulation factors in TP5 in our study (Table 1) are consistent with previously published averages [13, 17].

We compared LQP26 and TP5 to characterize the differences in coagulation factors at expiration for these two plasma products (Table 2). The differences in fibrinogen, PC, FVII, and FVIII have wide 95% credible intervals that contain 0 and thus support that LQP26 and TP5 have similar levels of these coagulation factors. In contrast, the posterior mean difference in PS between LQP26 and TP5 was -33.6% with a 95% credible interval of -47.7% to -18.8%, providing strong evidence that PS is substantially lower in LQP26 than in TP5. The posterior mean difference in FV was -11.3% (95% CI: -19.3, -2.82), which indicates that FV is significantly lower in LQP26 than TP5 with a smaller magnitude than PS.

We quantified the changes in coagulation factor activity during storage in liquid plasma units using multilevel piecewise linear regression models in which the first slope parameter ($\bar{\beta}$) is the average rate of change per day from mid-expiration (Day 15) to expiration (Day 26) and the second slope parameter ($\bar{\gamma}$) is the average rate of change from expiration to one day after expiration (Day 27). The posterior mean rates of change and 95% credible intervals of these parameters for all six coagulation factors are shown in Table 2.

FVII demonstrated a considerable decrease from Day 15 to Day 26 with a posterior mean rate of change of -3.49% per day (95% CI: -5.50, -1.41). The other coagulation factors had rates of changes from Day 15 to Day 26 with small effect sizes and credible intervals close to 0, indicating strong statistical evidence for small magnitudes of change in factor activity during storage compared to the large decrease observed for FVII. Fibrinogen and FV showed slight increases during storage with posterior mean rates of change of 1.31 mg/dL per day (95% CI: -0.57, 3.18) and 0.57% per day (95% CI: 0.06, 1.08), respectively, with credible intervals that are close to or include 0. Similarly, PC, PS, and FVIII had small decreases during storage posterior mean rates of change of -1.00% per day (95% CI: -1.83, -0.18), -0.50% per day (95% CI: -1.34, 0.32), and -0.58% (95% CI: -1.19, 0.04), respectively, with credible intervals that are close to or include 0.

From Day 26 to Day 27, all coagulation factors had small posterior mean rates of change with wide 95% credible intervals that include 0. These posterior distributions provide strong evidence that there are no significant changes in all six coagulation factors one day after expiration and indicate that changes in coagulation factors occur substantially before expiration during storage.

Discussion

Liquid plasma offers an extended shelf life compared to thawed plasma while retaining most essential coagulation factors needed for acute and emergent resuscitation needs. Our study evaluated fibrinogen, FV, FVII, FVIII, PS, and PC in a considerable number of LQP units during days of storage that would be typically found in inventory for blood banks and compared the activity of these coagulation factors to thawed plasma. We found that LQP has high fibrinogen and protein C activity levels similar to FFP and PF24 but contains lower levels of protein S, FV, FVII, and FVIII. These results are generally consistent with previously published findings as Matijevic et al. observed similarly high activity of fibrinogen and protein C and lower levels of protein S, FV, and FVIII, and Meledeo et. al found similar lower levels of FV and FVIII [9, 18].

The piecewise linear regression analysis demonstrated that FVII decreases during storage whereas fibrinogen, FV, FVIII, PC, and PS either do not change or

change to a small degree from Day 15 to Day 27. These results are consistent with FVII being a labile coagulation factor in plasma products but then suggest that the other five coagulation factors can be considered stable in liquid plasma during this period of storage. Our conclusions about FVII partially agree with one study that observed an initial decline in FVII in the first 10–15 days of storage and then a subsequent increase in FVII but disagrees with another study that saw an increase in FVII during storage [9, 19]. However, the effect size and significance of the findings from these respective studies are unclear as Matijevic et al. had descriptive statistics without statistical modeling and Gosselin et al. used second-order polynomial regression without a clear casual interpretation. In addition, methodological differences could explain some of these discrepancies as our study and Gosselin et al. analyzed samples that were frozen and thawed while Matijevic et al. tested fresh samples.

The findings of our comparison between LQP and TP strongly support that LQP is a viable alternative to thawed plasma for acute plasma resuscitation needs. The activity of fibrinogen, FVII, FVIII, and PC in LQP26 remained comparable to TP5 at levels similar to previously reported values [17, 20, 21]. In contrast, we found that PS levels are considerably lower in LQP26 than in TP5 and that FV activity is lower with a smaller magnitude in LQP26. However, fibrinogen loss is one of the major concerns in acute trauma settings, and since fibrinogen activities are similar in LQP and TP5, LQP can be used a readily available plasma product for acute resuscitation indications until frozen plasma can be thawed [18]. In addition, FVII has comparable activity in LQP and TP5 with an average activity of 55.0% in LQP27, which is sufficient for immediate coagulation [22].

In our hospital system, LQP units are initially delivered to the main hospital, where they are irradiated and then distributed to the smaller satellite and community hospitals in the system. By the time LQP reaches inventory in these other hospitals, they are typically 10–15 days old, and LQP units that are issued can be anywhere from 15 to 26 days old. Although we found that PS and FV are lower in LQP26 compared to TP5, we also found that the most important hemostatic coagulation factors, particularly fibrinogen and FVII, are similar in LQP26 and TP5. These findings help to justify using primarily LQP in our hospital system as

an alternative to TP for acute resuscitation needs while allowing for more flexibility for managing plasma inventory. We aim that the results of the comparison between LQP26 and TP5 can provide guidance in resources about plasma components, such as the Circulation of Information [13].

The stability of the coagulation factors from Day 26 to Day 27 seen in our study warrants more investigation if the shelf life of liquid plasma can be extended beyond 26 days. One preclinical study observed that the activity levels of FV and FVIII significantly decreased from Day 0 to Day 40 of storage but saw stable activity of fibrinogen throughout this period. The observed decrease in this study likely occurred in the first two weeks of storage and thus does not conflict with our results that FV, FVIII, and other labile coagulation factors are stable after Day 15. Additionally, clinical data show no significant difference in patient outcomes between those receiving older versus newer LQP units, supporting this perspective [7]. Further studies measuring additional coagulation factors at later time points will be needed to confirm the longevity of LQP.

Our study provides more evidence that liquid plasma is a viable alternative to thawed plasma as an effective strategy to quickly provide plasma products for initial emergency resuscitation while allowing sufficient time for thawing frozen plasma. LQP provides both volume expansion and coagulation support while significantly reducing blood product wastage due to its longer shelf life compared to thawed plasma.

Acknowledgements

N.Y., C.G., N.P., E.S.L., C.A.T., H.M.R. designed the study. N.Y., C.G., N.P., E.S.L. collected samples and maintained the study database. P.B. analyzed the samples in the lab. C.A.T., E.L.S., and H.M.R. supervised the study. N.Y. and E.S.L. analyzed the data. N.Y., C.G. and E.S.L. wrote the manuscript. All authors reviewed and approved the manuscript.

We thank all the blood bank staff at Bridgeport Hospital, Milford Campus, and Yale New Haven Hospital and the hematology staff at Yale New Haven Hospital for their help in this project.

References

1 Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015; 313: 471-82.

2 Allen CJ, Shariatmadar S, Meizoso JP, Hanna MM, Mora JL, Ray JJ, et al. Liquid plasma use during "super" massive transfusion protocol. J Surg Res. 2015; 199: 622-8.

3 Watson JJ, Pati S, Schreiber MA. Plasma Transfusion: History, Current Realities, and Novel Improvements. Shock. 2016; 46: 468-79.

4 Beattie G, Cohan CM, Ng VL, Victorino GP. Liquid plasma: A solution to optimizing early and balanced plasma resuscitation in massive transfusion. J Trauma Acute Care Surg. 2020; 89: 488-95.

5 Chehab M, Ditillo M, Obaid O, Nelson A, Poppe B, Douglas M, et al. Never-frozen liquid plasma transfusion in civilian trauma: a nationwide propensity-matched analysis. J Trauma Acute Care Surg. 2021; 91: 200-5.

6 Fadeyi EA, Saha AK, Soltani S, Naal T, Palmer R, Bakht A, et al. A comparison between liquid group A plasma and thawed group A plasma for massive transfusion activation in trauma patients. Vox Sang. 2022; 117: 513-9.

7 Norda R, Andersson TM, Edgren G, Nyren O, Reilly M. The impact of plasma preparations and their storage time on short-term posttransfusion mortality: a population-based study using the Scandinavian Donation and Transfusion database. J Trauma Acute Care Surg. 2012; 72: 954-60.

8 Connor JP, Jaladi S, Cao W, Lehman DM, Raife TJ. Expanded use of liquid plasma in non-emergency transfusions: A single academic institution experience. Transfusion. 2025; 65: 466-75.

9 Matijevic N, Wang YW, Cotton BA, Hartwell E, Barbeau JM, Wade CE, et al. Better hemostatic profiles of never-frozen liquid plasma compared with thawed fresh frozen plasma. J Trauma Acute Care Surg. 2013; 74: 84-90; discussion -1.

10 Cao Y, Dua A, Matijevic N, Wang YW, Pati S, Wade CE, et al. Never-frozen liquid plasma blocks endothelial permeability as effectively as thawed fresh frozen plasma. J Trauma Acute Care Surg. 2014; 77: 28-33; discussion

11 Kruschke JK. Bayesian estimation supersedes the t test. J Exp Psychol Gen. 2013; 142: 573-603.

12 Brilleman SL, Howe LD, Wolfe R, Tilling K. Bayesian Piecewise Linear Mixed Models With a Random Change Point: An Application to BMI Rebound in Childhood. Epidemiology. 2017; 28: 827-33.

13 Circular for Information for the Use of Human Blood and Blood Components. AABB, 2024.

14 Stan Development Team, Stan Reference Manual, Version 2.36. 2024. https://mc-stan.org

15 R Core Team. R: A Langauge and Environment for Statistical Computing. 2024.

16 McElreath R. Statistical Rethinking: A Bayesian Course with Examples in R and Stan. ed Second edition. Boca Raton, FL; 2020.

17 Scott E, Puca K, Heraly J, Gottschall J, Friedman K. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. Transfusion. 2009; 49: 1584-91.

18 Meledeo MA, Peltier GC, McIntosh CS, Bynum JA, Corley JB, Cap AP. Coagulation function of never frozen liquid plasma stored for 40 days. Transfusion. 2021; 61 Suppl 1: S111-S8.

19 Gosselin RC, Marshall C, Dwyre DM, Gresens C, Davis D, Scherer L, et al. Coagulation profile of liquid-state plasma. Transfusion. 2013; 53: 579-90.

20 Cardigan R, Green L. Thawed and liquid plasma--what do we know? Vox Sang. 2015; 109: 1-10.

21 McCullagh J, Booth C, Lancut J, Platton S, Richards P, Green L. Every minute counts: A comparison of thawing times and haemostatic quality of plasma thawed at 37 degrees C and 45 degrees C using four different methods. Transfus Med. 2024; 34: 304-10.

22 Edmunds LH. Hemostatic problems in surgical patients. ed 4th: Lippincott Williams and Wilkins; 2001.



Figure 1. Coagulation factor activity in liquid plasma and thawed plasma. (A) Coagulation factor activity levels of fibrinogen, Protein C, Protein S, Factor V, Factor VII, and Factor VIII were measured in liquid plasma units (n = 26) on Day 15 of storage (LQP15), on Day 26 of storage (LQP26), and on Day 27 of storage (LQP27), which is one

day after expiration. The same coagulation factors were measured in thawed plasma units on Day 5 of storage (n = 24). The box-and-whisker plots depict the minimum, first quartile (25th percentile), median, third quartile (75th percentile), and maximum values. (B) Multilevel piecewise linear regression was performed for all coagulation factors in liquid plasma units to characterize how coagulation factor activity changes with storage time. Plots depict posterior mean fits with 95% credible interval envelopes with individual factor activity measurements as jittered points.

	Coagulation Factor Level: Posterior Mean (95% Credible Interval)			
	Liquid Plasma			Thawed Plasma
Analyte	**Day 15 (n = 26)**	**Day 26 (n = 26)**	**Day 27 (n = 26)**	**Day 5 (n = 24)**
Fibrinogen (mg/dl)	241 (228, 254)	257 (242, 275)	252 (238, 268)	247 (236, 256)
Protein C activity (%)	110.6 (102.8, 118.7)	102.1 (97.3, 107.8)	100.4 (96.3, 105.5)	111.3 (105.5, 117.3)
Protein S activity (%)	35.3 (27.1, 43.6)	30.5 (26.4, 35.0)	28.0 (23.0, 33.4)	64.9 (50.2, 78.3)
Factor V (%)	37.0 (33.9, 40.8)	46.0 (42.4, 49.8)	42.6 (38.9, 46.8)	58.4 (52.0, 64.3)
Factor VII (%)	66.1 (55.0, 80.0)	55.0 (50.6, 59.6)	55.0 (50.4, 60.2)	62.2 (56.1, 69.1)
Factor VIII (%)	56.0 (51.8, 60.2)	49.6 (44.5, 54.7)	48.8 (44.0, 53.7)	55.0 (48.8, 61.2)

Table 1. Average coagulation factor activity in liquid plasma and thawed plasma. Estimation of mean coagulation factor activity of fibrinogen, Protein C, Protein S, Factor V, Factor VII, and Factor VIII levels in liquid plasma at Day 15 of storage, liquid plasma at Day 26 of storage (day of expiration), liquid plasma at Day 27 of storage (1 day of expiration), and thawed plasma at Day 5 of storage (day of expiration). The table shows the posterior mean estimates with 95% credible intervals in parentheses.

Analyte	**Difference in activity between LQP26 and TP5**	**Change in factor activity per day in liquid plasma**	
		$\bar{\beta}$**: Day 15 to Day 26**	$\bar{\gamma}$**: Day 26 to Day 27**
Fibrinogen (mg/dL)	12.9 (-8.82, 34.5)	1.31 (-0.57, 3.18)	-2.00 (-16.8, 12.9)
Protein C (%)	-8.23 (-17.5, 1.4)	-1.00 (-1.83, -0.176)	-0.26 (-3.76, 3.19)
Protein S (%)	-33.6 (-47.7, -18.8)	-0.50 (-1.34, 0.324)	-0.88 (-4.24, 2.55)
Factor V (%)	-11.3 (-19.3, -2.82)	0.57 (0.06, 1.08)	-1.09 (-4.29, 2.12)
Factor VII (%)	-8.2 (-18.2, 1.4)	-3.49 (-5.50, -1.41)	-0.17 (-3.58, 3.20)
Factor VIII (%)	-5.22 (-14.0, 3.59)	-0.58 (-1.19, 0.04)	-0.18 (-3.63, 3.29)

Table 2. Difference in coagulation factor activity between LQP26 and TP5 and changes in factor activity during storage for liquid plasma. Posterior mean estimates are shown with 95% credible intervals in parentheses.